Umeclidinium is a prescription antimuscarinic bronchodilator available in the form of an inhaler device. It is used to treat chronic obstructive pulmonary disease (COPD) and is available in ...

Cash Position: Ended the quarter with $178.36 million in cash and cash equivalents, down from $193.51 million at the end of the previous quarter.

Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva ...

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and ...

Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and critical care ...

Innoviva is entitled to receive royalties from GSK on sales of RELVAR ®/BREO ® ELLIPTA ® and ANORO ® ELLIPTA ®. Innoviva's other innovative healthcare assets include infectious disease and critical ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...